JO2178B1 - Treatment of invasive diseases, using selected anti-PAR materials - Google Patents

Treatment of invasive diseases, using selected anti-PAR materials

Info

Publication number
JO2178B1
JO2178B1 JO2000172A JOP20000172A JO2178B1 JO 2178 B1 JO2178 B1 JO 2178B1 JO 2000172 A JO2000172 A JO 2000172A JO P20000172 A JOP20000172 A JO P20000172A JO 2178 B1 JO2178 B1 JO 2178B1
Authority
JO
Jordan
Prior art keywords
emphysema
treatment
rar
agonists
retinoid antagonists
Prior art date
Application number
JO2000172A
Other languages
Arabic (ar)
English (en)
Inventor
نايت بيلوني بولا
كلوز ميشيل
Original Assignee
اف . هوفمان لاروش ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان لاروش ايه جي filed Critical اف . هوفمان لاروش ايه جي
Application granted granted Critical
Publication of JO2178B1 publication Critical patent/JO2178B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JO2000172A 1999-10-19 2000-10-12 Treatment of invasive diseases, using selected anti-PAR materials JO2178B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19

Publications (1)

Publication Number Publication Date
JO2178B1 true JO2178B1 (en) 2003-04-23

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2000172A JO2178B1 (en) 1999-10-19 2000-10-12 Treatment of invasive diseases, using selected anti-PAR materials

Country Status (33)

Country Link
US (1) US6300350B1 (OSRAM)
EP (1) EP1225878B1 (OSRAM)
JP (2) JP4074458B2 (OSRAM)
KR (1) KR100485581B1 (OSRAM)
CN (1) CN1201730C (OSRAM)
AR (1) AR029648A1 (OSRAM)
AT (1) ATE344661T1 (OSRAM)
AU (1) AU777325B2 (OSRAM)
BR (1) BR0015225A (OSRAM)
CA (1) CA2387844C (OSRAM)
CY (1) CY1105941T1 (OSRAM)
CZ (1) CZ20021657A3 (OSRAM)
DE (1) DE60031790T2 (OSRAM)
DK (1) DK1225878T3 (OSRAM)
ES (1) ES2274810T3 (OSRAM)
HR (1) HRP20020329A2 (OSRAM)
HU (1) HUP0203295A3 (OSRAM)
IL (1) IL149151A0 (OSRAM)
JO (1) JO2178B1 (OSRAM)
MA (1) MA26835A1 (OSRAM)
MX (1) MXPA02003843A (OSRAM)
MY (1) MY129001A (OSRAM)
NO (1) NO328738B1 (OSRAM)
NZ (1) NZ518118A (OSRAM)
PE (1) PE20010678A1 (OSRAM)
PL (1) PL357499A1 (OSRAM)
PT (1) PT1225878E (OSRAM)
RS (1) RS50165B (OSRAM)
RU (1) RU2257383C2 (OSRAM)
TR (1) TR200201071T2 (OSRAM)
TW (1) TWI288639B (OSRAM)
WO (1) WO2001030326A1 (OSRAM)
ZA (1) ZA200202576B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
AU2002340886B2 (en) 2001-09-18 2008-01-31 F. Hoffmann-La Roche Ag Substituted urea retinoid agonists II
WO2003024921A1 (en) * 2001-09-18 2003-03-27 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20070104809A1 (en) 2003-08-22 2007-05-10 Danisco A/S Composition comprising a bacteriocin and an extract from a plant of the labiatae family
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
EP2394647A1 (en) * 2006-11-02 2011-12-14 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
PL3721880T3 (pl) 2010-09-01 2022-05-23 Thomas Jefferson University Kompozycja i sposób naprawy i regeneracji mięśni
US9949996B2 (en) 2011-06-24 2018-04-24 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
EP2736332A4 (en) * 2011-07-29 2015-03-18 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
CN104995178B (zh) 2012-12-17 2018-06-26 帕里昂科学公司 3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
RU2015129065A (ru) 2012-12-17 2017-01-25 Пэрион Сайенсиз, Инк. Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов
EP4083029A1 (en) 2013-08-20 2022-11-02 University of Washington through its Center for Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydroxylase
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CA2168021C (en) * 1993-08-19 2007-07-03 Guy Rosalia Eugene Van Lommen Vasoconstrictive dihydrobenzopyran derivatives
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
ATE185799T1 (de) * 1995-02-24 1999-11-15 Hoffmann La Roche Retinoide
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) * 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
CA2307879C (en) * 1997-11-12 2009-12-22 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
AU4225500A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2000061182A2 (en) 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a selective rar-alpha agonist
DK1206436T3 (da) * 1999-08-02 2005-02-14 Hoffmann La Roche Retinoider til behandling af emfysem
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
MXPA02003843A (es) 2002-09-30
AR029648A1 (es) 2003-07-10
EP1225878A1 (en) 2002-07-31
CN1201730C (zh) 2005-05-18
RU2257383C2 (ru) 2005-07-27
TR200201071T2 (tr) 2002-08-21
BR0015225A (pt) 2002-07-16
DE60031790T2 (de) 2007-09-20
MY129001A (en) 2007-03-30
ZA200202576B (en) 2003-09-23
HUP0203295A2 (hu) 2003-01-28
CA2387844A1 (en) 2001-05-03
PT1225878E (pt) 2007-01-31
AU1137401A (en) 2001-05-08
KR20020043640A (ko) 2002-06-10
DK1225878T3 (da) 2007-03-05
EP1225878B1 (en) 2006-11-08
HUP0203295A3 (en) 2003-04-28
US6300350B1 (en) 2001-10-09
ATE344661T1 (de) 2006-11-15
NO20021823L (no) 2002-04-18
HK1051002A1 (zh) 2003-07-18
PE20010678A1 (es) 2001-07-04
WO2001030326A1 (en) 2001-05-03
IL149151A0 (en) 2002-11-10
JP4850791B2 (ja) 2012-01-11
TWI288639B (en) 2007-10-21
CA2387844C (en) 2009-04-14
CY1105941T1 (el) 2011-04-06
NO20021823D0 (no) 2002-04-18
CN1382042A (zh) 2002-11-27
JP2003512418A (ja) 2003-04-02
AU777325B2 (en) 2004-10-14
NZ518118A (en) 2004-02-27
KR100485581B1 (ko) 2005-04-27
PL357499A1 (pl) 2004-07-26
CZ20021657A3 (cs) 2002-10-16
MA26835A1 (fr) 2004-12-20
HRP20020329A2 (en) 2004-04-30
ES2274810T3 (es) 2007-06-01
JP4074458B2 (ja) 2008-04-09
RS50165B (sr) 2009-05-06
YU29002A (sh) 2005-06-10
DE60031790D1 (de) 2006-12-21
NO328738B1 (no) 2010-05-03
JP2007302689A (ja) 2007-11-22

Similar Documents

Publication Publication Date Title
JO2178B1 (en) Treatment of invasive diseases, using selected anti-PAR materials
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
AU2003234231A1 (en) New polyarylates for drug delivery and tissue engineering
MXPA05005527A (es) Forma de dosis de alergeno.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
MY125978A (en) Admantane derivatives
MXPA97002401A (es) Agente antiinflamatorio para uso externo.
ME00578A (en) Use of gastrointestinal lipase inhibitors
AU2855399A (en) Vascularization inhibitors
BG108516A (en) Pharmaceutical formulation
AU2003297199A8 (en) Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
IL165213A0 (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilizationmedicament or diagnostic agent and medicament containing same
MY136880A (en) Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
AU3862997A (en) Stable derivatives of ubiquinole, processes for their production and pharmaceutical use thereof
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
AR003001A1 (es) Composicion farmaceutica estimuladora de la osteogenesis.
IT1321290B1 (it) Metodo per la sterilizzazione di condotti di alimentazione di fluidoa strumenti medici, ed in particolare odontoiatrici.
IL173918A0 (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same
IL147500A0 (en) Method for delivery of therapeutic agents using a solution of dextrin
AU2003264094A1 (en) Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
UY26415A1 (es) Tratamiento del enfisema utilizando antagonistas retinoides selectivos rar